Takeda, a leading Japanese pharmaceutical company, has commenced construction on a $230 million expansion of its Los Angeles production facility. This significant investment will result in the largest plasma fractionation site for Takeda worldwide and is expected to boost production by two million liters annually.
The expansion project involves repurposing an existing building and utilizing existing site infrastructure, which will greatly reduce the time typically required for planning and obtaining permits for new construction. Moreover, this approach aligns with Takeda’s commitment to minimizing environmental impact through responsible resource management and waste reduction.
According to Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda, the United States plays a crucial role in their global manufacturing network and contributes significantly to their supply chain resilience. The increased manufacturing capacity at the LA facility will enable Takeda to meet growing demand for plasma-derived therapies globally while fulfilling its mission of providing life-saving treatments for patients in need.
This article was originally published on Connect CRE website.
